• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by OSR Holdings Inc.

    4/1/25 3:00:20 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care
    Get the next $OSRH alert in real time by email
    NT 10-K 1 ea0236618-nt10k_osr.htm NOTIFICATION OF LATE FILING

     

     

        OMB APPROVAL
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     OMB Number: 3235-0058
       Expires: April 30, 2025 
       Estimated average burden hours per response. 2.50

      

      SEC FILE NUMBER
     

    001-41390

         
        CUSIP NUMBER
     

    68840D102

     

    (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K  
      ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

      

       
     

    For Period Ended: December 31, 2024


    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
     
    For the Transition Period Ended: ____________________

       

    Read Instruction (on back page) Before Preparing Form. Please Print or Type. 
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. 

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    PART I — REGISTRANT INFORMATION

     

     

    OSR HOLDINGS, INC.

    Full Name of Registrant
     
    Bellevue Life Sciences Acquisition Corp.
    Former Name if Applicable
     

    10900 NE 4th Street, Suite 2300

    Address of Principal Executive Office (Street and Number)
     

    Bellevue, WA 98004

    City, State and Zip Code

      

     

      

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      ☒   (a)

    The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;

        (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

        (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    2 of 4

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    OSR Holdings, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company has experienced a delay in completing the necessary disclosures and finalizing its financial statements with its independent registered public accounting firm in connection with its Form 10-K. The Company anticipates that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

     

    PART IV — OTHER INFORMATION

               
    (1) Name and telephone number of person to contact in regard to this notification
     
     

    Kuk Hyoun Hwang

     

    (425)

     

    635-7700

      (Name)   (Area Code)   (Telephone Number)
     
    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     
      Yes  ☒     NO  ☐
     
       
     
    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     
      Yes  ☒     NO  ☐
     
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    For the year ended December 31, 2024, the Company expects to report net loss of $1,039,729 which is comprised of general and administrative expenses of $2,184,596, provision for income taxes of $295,728 and interest expense of $11,814, offset by interest earned on investments held in the trust account of $1,450,228 and interest income of $2,181.

     

    For the year ended December 31, 2023, the Company had a net income of $403,780 which was comprised of general and administrative expenses of $1,830,700, provision for income taxes of $540,811, and interest earned on investments held in the trust account of $2,775,291.

     

    The amounts reported above for the year ended December 31, 2024 are still under review by the Company’s independent registered public accounting firm and accounting staff and may differ once reported in the Form 10-K to be filed by the Company.

     

    Forward-Looking Statements

     

    Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words and phrases such as “will”, “may”, “should”, “future”, “promptly”, “expect”, “estimate”, “anticipate,” “intends”, “plans”, “subject to”, and “change” and other similar expressions that predict or indicate future events or trends or that are not statements of historical fact. Such statements may include, but are not limited to, the filing of the Form 10-K and the results of the ongoing review. These statements are based on current expectations on the date hereof and involve a number of risks and uncertainties that may cause actual results to differ significantly. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, including without limitation a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to file its Form 10-K within the fifteen-day extension permitted by the rules of the SEC, and the possibility that the ongoing review may identify errors or control deficiencies in the Company’s accounting practices. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise.

     

    3 of 4

     

    OSR HOLDINGS, INC.

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:  

    April 1, 2025

      By:

    /s/ Kuk Hyoun Hwang

          Name:

    Kuk Hyoun Hwang

          Title:

    Chief Executive Officer

      

    INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the Form.

     

     

    ATTENTION 
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    4 of 4

    Get the next $OSRH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSRH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

      SEOUL, South Korea and ZUG, Switzerland, May 22, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a public company dedicated to advancing innovation in healthcare and wellness, announced today that it has entered into a Memorandum of Understanding (MOU) with BCM Europe AG, its major shareholder, and Taekwondo Cooperative (TKD Coop), a global Taekwondo community organization, to explore the joint development of a security token, provisionally named the "OSRH Token". The initiative aims to enhance access to crypto-based liquidity and provide a basis for OSRH to launch crypto treasury strategies.

      5/22/25 7:36:00 AM ET
      $BLAC
      $OSRH
      Blank Checks
      Finance
      Medical/Dental Instruments
      Health Care
    • Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

      PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ:OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference, taking place May 2–6, 2025, at the University of Pennsylvania in Philadelphia. The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year's program highlights novel technologies and fundamental r

      5/2/25 7:30:00 AM ET
      $OSRH
      Medical/Dental Instruments
      Health Care
    • Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

      SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ:OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market. Activin/BMP7 Chimera Protein Technology Registered in China Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoar

      4/9/25 7:54:00 AM ET
      $OSRH
      Medical/Dental Instruments
      Health Care

    $OSRH
    SEC Filings

    See more
    • SEC Form 10-Q filed by OSR Holdings Inc.

      10-Q - OSR Holdings, Inc. (0001840425) (Filer)

      5/20/25 4:00:55 PM ET
      $OSRH
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-Q filed by OSR Holdings Inc.

      NT 10-Q - OSR Holdings, Inc. (0001840425) (Filer)

      5/15/25 5:17:55 PM ET
      $OSRH
      Medical/Dental Instruments
      Health Care
    • OSR Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - OSR Holdings, Inc. (0001840425) (Filer)

      5/12/25 4:05:17 PM ET
      $OSRH
      Medical/Dental Instruments
      Health Care

    $OSRH
    Leadership Updates

    Live Leadership Updates

    See more
    • OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

      BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a

      3/25/25 7:00:00 AM ET
      $OSRH
      Medical/Dental Instruments
      Health Care